OBJECTIVE: To evaluate whether C-reactive protein (CRP) serum levels can be used as prognostic parameter in patients with vulvar cancer. STUDY DESIGN: CRP serum levels were measured at the time of first diagnosis of squamous cell vulvar cancer. Sixty-seven patients were enrolled; results were correlated to clinical data. RESULTS: Mean CRP serum levels in patients with vulvar cancer were 0.8 (0.80)mg/dL. CRP serum levels were significantly associated with lymph node involvement (p=0.003), but not with tumor stage (p=0.03), histological grade (p=0.86) and patients' age (p=0.64). Univariate analysis showed lymph node involvement, tumor stage and histological grade, but not CRP serum levels and patients' age to be associated with overall survival. A multivariable analysis determined only lymph node involvement as independent prognostic parameter for disease-free interval and overall survival. CONCLUSION: CRP serum levels are closely associated with lymph node status but cannot be used as prognostic parameter in patients with vulvar cancer.
OBJECTIVE: To evaluate whether C-reactive protein (CRP) serum levels can be used as prognostic parameter in patients with vulvar cancer. STUDY DESIGN:CRP serum levels were measured at the time of first diagnosis of squamous cell vulvar cancer. Sixty-seven patients were enrolled; results were correlated to clinical data. RESULTS: Mean CRP serum levels in patients with vulvar cancer were 0.8 (0.80)mg/dL. CRP serum levels were significantly associated with lymph node involvement (p=0.003), but not with tumor stage (p=0.03), histological grade (p=0.86) and patients' age (p=0.64). Univariate analysis showed lymph node involvement, tumor stage and histological grade, but not CRP serum levels and patients' age to be associated with overall survival. A multivariable analysis determined only lymph node involvement as independent prognostic parameter for disease-free interval and overall survival. CONCLUSION:CRP serum levels are closely associated with lymph node status but cannot be used as prognostic parameter in patients with vulvar cancer.
Authors: Christine Bekos; Stephan Polterauer; Veronika Seebacher; Thomas Bartl; Elmar Joura; Alexander Reinthaller; Alina Sturdza; Reinhard Horvat; Richard Schwameis; Christoph Grimm Journal: Arch Gynecol Obstet Date: 2019-08-29 Impact factor: 2.344
Authors: Michal Mleko; Kazimierz Pitynski; Elzbieta Pluta; Aleksandra Czerw; Katarzyna Sygit; Beata Karakiewicz; Tomasz Banas Journal: Cancer Manag Res Date: 2021-07-09 Impact factor: 3.989